Biofrontera to Present at Lytham Partners Fall 2025 Investor Conference

Biofrontera Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will have a webcast presentation and host one-on-one meetings with investors. The webcast can be accessed through the conference home page or directly at https://app.webinar.net/wWqPp4Yr0kD. Biofrontera is a biopharmaceutical company specializing in dermatological products, including Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions.

Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in dermatological products, has announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will deliver a webcast presentation at 1:15 p.m. ET and conduct one-on-one meetings with investors throughout the virtual event.

The webcast presentation will be held at 1:15 p.m. ET on September 30, 2025. Investors can access the webcast through the conference home page at [https://lythampartners.com/fall2025/](https://lythampartners.com/fall2025/) or directly at [https://app.webinar.net/wWqPp4Yr0kD](https://app.webinar.net/wWqPp4Yr0kD). The webcast will also be available for replay following the event.

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at [https://lythampartners.com/fall2025invreg/](https://lythampartners.com/fall2025invreg/).

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on the development and treatment of dermatological conditions, with a particular emphasis on photodynamic therapy (PDT). The company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of actinic keratosis (AK) and pre-cancerous skin lesions, which may progress to invasive skin cancers. Biofrontera is also conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne.

For more information, visit [www.biofrontera-us.com](http://www.biofrontera-us.com) and follow Biofrontera on LinkedIn and X.